Boundless Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	13.33	12.16	9.31	6.02
Research & Development	46.26	42.64	37.16	19.28
Operating Expenses	59.59	54.8	46.47	25.3
Operating Income	-59.59	-54.8	-46.47	-25.3
Interest & Investment Income	6.31	5.28	0.67	0.1
Other Non Operating Income (Expenses)	0.14	0.08	-0.1	-0.01
Pretax Income	-53.15	-49.43	-45.9	-25.21
Net Income	-53.15	-49.43	-45.9	-25.21
Net Income to Common	-53.15	-49.43	-45.9	-25.21
Shares Outstanding (Basic)	1	1	1	1
Shares Outstanding (Diluted)	1	1	1	1
Shares Change (YoY)	9.39%	10.78%	27.56%	-
EPS (Basic)	-43.04	-40.65	-41.81	-29.29
EPS (Diluted)	-43.04	-40.65	-41.81	-29.29
Free Cash Flow	-51.17	-47.49	-40.66	-25.28
Free Cash Flow Per Share	-41.44	-39.05	-37.04	-29.38
EBITDA	-58.61	-53.84	-45.53	-24.62
D&A For EBITDA	0.98	0.96	0.94	0.68
EBIT	-59.59	-54.8	-46.47	-25.3

Source: S&P Capital IQ. Standard template.